RGEN
NASDAQ
$145.49
Repligen Corp (RGEN)
Repligen Corporation develops and markets bioprocessing systems and technologies for use in the biologic drug manufacturing process in North America, Europe, Asia Pacific, and internationally. The company is headquartered in Waltham, Massachusetts.
Sector:
Healthcare
Industry:
Medical Instruments & Supplies
Buy
Target: $178.05 (+22.38%)
Market Cap
$8.35B
PEG Ratio
0.62
Revenue 5Y CAGR
+20.34%
Forward P/E
74.63
Price Chart
Valuation
Market Cap$8.35B
P/E162.20
Forward P/E74.63
PEG0.62
P/S10.87
P/B3.88
Profitability
Total Revenue (TTM)$763M
Gross Profit (TTM)$406M
EBITDA$144M
Profit Margin4.3%
Operating Margin8.2%
EPS$0.91
Financial Health
Debt-to-Equity26%
Free Cash Flow Yield1.27%
Growth & Risk
EPS 5Y CAGR+9.09%
Revenue 5Y CAGR+20.34%
FCF 5Y CAGR+18.20%
Beta (5Y)1.32
Sharpe Ratio0.49